Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1818.53
OMPI's Cash to Debt is ranked lower than
99.99% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. OMPI: 1818.53 )
Ranked among companies with meaningful Cash to Debt only.
OMPI' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 298.08 Max: No Debt
Current: 1818.53
Equity to Asset 0.66
OMPI's Equity to Asset is ranked lower than
99.99% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OMPI: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
OMPI' s Equity to Asset Range Over the Past 10 Years
Min: -0.82  Med: 0.62 Max: 0.71
Current: 0.66
-0.82
0.71
Interest Coverage 1959.20
OMPI's Interest Coverage is ranked lower than
57% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OMPI: 1959.20 )
Ranked among companies with meaningful Interest Coverage only.
OMPI' s Interest Coverage Range Over the Past 10 Years
Min: 2  Med: 1053.70 Max: 1000
Current: 1959.2
2
1000
F-Score: 6
Z-Score: 16.58
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 22.70
OMPI's Operating margin (%) is ranked lower than
99.99% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. OMPI: 22.70 )
Ranked among companies with meaningful Operating margin (%) only.
OMPI' s Operating margin (%) Range Over the Past 10 Years
Min: 7.6  Med: 22.70 Max: 38
Current: 22.7
7.6
38
Net-margin (%) 13.80
OMPI's Net-margin (%) is ranked lower than
99.99% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. OMPI: 13.80 )
Ranked among companies with meaningful Net-margin (%) only.
OMPI' s Net-margin (%) Range Over the Past 10 Years
Min: 2.5  Med: 12.90 Max: 25
Current: 13.8
2.5
25
ROE (%) 26.90
OMPI's ROE (%) is ranked lower than
99.99% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. OMPI: 26.90 )
Ranked among companies with meaningful ROE (%) only.
OMPI' s ROE (%) Range Over the Past 10 Years
Min: 15.7  Med: 26.90 Max: 252.1
Current: 26.9
15.7
252.1
ROA (%) 20.30
OMPI's ROA (%) is ranked lower than
99.99% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. OMPI: 20.30 )
Ranked among companies with meaningful ROA (%) only.
OMPI' s ROA (%) Range Over the Past 10 Years
Min: 3.3  Med: 17.40 Max: 28.9
Current: 20.3
3.3
28.9
ROC (Joel Greenblatt) (%) 153.60
OMPI's ROC (Joel Greenblatt) (%) is ranked lower than
99.99% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. OMPI: 153.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OMPI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 65.9  Med: 103.80 Max: 241.5
Current: 153.6
65.9
241.5
Revenue Growth (3Y)(%) 8.60
OMPI's Revenue Growth (3Y)(%) is ranked lower than
99.99% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. OMPI: 8.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OMPI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.2  Med: 5.70 Max: 14.4
Current: 8.6
-0.2
14.4
EBITDA Growth (3Y)(%) 13.70
OMPI's EBITDA Growth (3Y)(%) is ranked lower than
99.99% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. OMPI: 13.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OMPI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -0.80 Max: 50.5
Current: 13.7
0
50.5
EPS Growth (3Y)(%) 15.00
OMPI's EPS Growth (3Y)(%) is ranked lower than
99.99% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. OMPI: 15.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OMPI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.6  Med: 2.00 Max: 15
Current: 15
-10.6
15
» OMPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OMPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ENTA, NAS:PGNX, NAS:AGEN, NAS:MYOK, NAS:GERN, OTCPK:PTCHF, NAS:ACRS, NAS:OMER, NAS:ARNA, NAS:MNKD, NAS:SGMO, NAS:AMRN, OTCPK:ZLDPF, NAS:TLGT, NAS:OTIC, NAS:CYTK, NAS:XNPT, NAS:RVNC, NAS:SPPI, NAS:CTMX » details
Traded in other countries:O1P.Germany,


Obagi Medical Products, Inc. was founded as WorldWide Product Distribution, Inc. in 1988. OMP Acquisition Corporation was incorporated in California in October 1997 to purchase substantially all of the assets and to assume the accounts payable and related operating liabilities of WorldWide and subsequently changed its name to Obagi Medical Products, Inc. in December 1997. OMP, Inc. ('OMP') was incorporated in Delaware in November 2000. The Company is a specialty pharmaceutical company that develops, markets and sells, and is a provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems and related products in the physician-dispensed market. Obagi systems and products are designed to prevent and improve the most common and visible skin disorders in adult skin, including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, facial redness, and soft tissue deficits, such as fine lines and wrinkles. Its products have been developed to enhance the underlying health of patients' skin, and clinical studies have demonstrated that the use of its systems results in skin that looks and acts younger and healthier. The Company's systems and related products for the enhancement of skin health including: Obagi Nu-Derm System, Obagi Condition & Enhance Systems, Professional-C, ELASTIderm Eye and Décolletage, ELASTILash Eyelash Solution, CLENZIderm M.D. Systems, Obagi Rosaclear System, Tretinoin, Refissa, Metronidazole, Obagi Blue Peel Essential Kit, Blue Peel RADIANCE. The Company sells its products through a direct sales force in the United States and internationally through distribution partners in over 43 countries across North America, Central America, Europe, the Middle East and Asia. The Company's main competitors include SkinCeuticals, SkinMedica, Inc., Valeant Pharmaceuticals International, Allergan, Inc., IS Clinical, PhotoMedex, Inc., Jan Marini, La-Roche Posay, Dermalogica, The Estee Lauder Companies Inc., Helene Curtis Industries, Inc., L'Oreal S.A., Matrix Essentials, Inc., Procter & Gamble Company, Johnson & Johnson, Revlon, Inc., Unilever N.V, Medicis Pharmaceutical Corporation, Stiefel, Galderma Laboratories, L.P, Syneron Medical Ltd., CoolTouch Corporation, Cutera, Inc., Cynosure, Inc., Lumenis Ltd., Reliant Technologies, Inc. and Solta Medical, Inc. The Company and its suppliers or third-party manufacturers may also be subject to regulations under other federal, state, and local laws, including the Occupational Safety and Health Act, the Environmental Protection Act, the Clean Air Act and import, export and customs regulations as well as the laws and regulations of other countries.

Ratios

vs
industry
vs
history
P/E(ttm) 13.50
OMPI's P/E(ttm) is ranked higher than
56% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.09 vs. OMPI: 13.50 )
Ranked among companies with meaningful P/E(ttm) only.
OMPI' s P/E(ttm) Range Over the Past 10 Years
Min: 8.45  Med: 21.38 Max: 57.79
Current: 13.5
8.45
57.79
PE(NRI) 13.50
OMPI's PE(NRI) is ranked higher than
58% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 29.71 vs. OMPI: 13.50 )
Ranked among companies with meaningful PE(NRI) only.
OMPI' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 13.5
P/B 3.49
OMPI's P/B is ranked lower than
99.99% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. OMPI: 3.49 )
Ranked among companies with meaningful P/B only.
OMPI' s P/B Range Over the Past 10 Years
Min: 1.45  Med: 3.70 Max: 20.54
Current: 3.49
1.45
20.54
P/S 1.88
OMPI's P/S is ranked lower than
99.99% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. OMPI: 1.88 )
Ranked among companies with meaningful P/S only.
OMPI' s P/S Range Over the Past 10 Years
Min: 0.89  Med: 2.10 Max: 5.03
Current: 1.88
0.89
5.03
PFCF 12.78
OMPI's PFCF is ranked lower than
99.99% of the 147 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. OMPI: 12.78 )
Ranked among companies with meaningful PFCF only.
OMPI' s PFCF Range Over the Past 10 Years
Min: 7.95  Med: 16.40 Max: 38.21
Current: 12.78
7.95
38.21
EV-to-EBIT 13.98
OMPI's EV-to-EBIT is ranked lower than
99.99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. OMPI: 13.98 )
Ranked among companies with meaningful EV-to-EBIT only.
OMPI' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.1  Med: 10.90 Max: 24.5
Current: 13.98
4.1
24.5
EV-to-EBITDA 13.20
OMPI's EV-to-EBITDA is ranked lower than
99.99% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. OMPI: 13.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
OMPI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 13.2
PEG 1.34
OMPI's PEG is ranked lower than
99.99% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. OMPI: 1.34 )
Ranked among companies with meaningful PEG only.
OMPI' s PEG Range Over the Past 10 Years
Min: 0.68  Med: 1.73 Max: 11.6
Current: 1.34
0.68
11.6
Shiller P/E 18.92
OMPI's Shiller P/E is ranked lower than
99.99% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 56.77 vs. OMPI: 18.92 )
Ranked among companies with meaningful Shiller P/E only.
OMPI' s Shiller P/E Range Over the Past 10 Years
Min: 16.8  Med: 20.92 Max: 38.52
Current: 18.92
16.8
38.52
Current Ratio 3.91
OMPI's Current Ratio is ranked lower than
99.99% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. OMPI: 3.91 )
Ranked among companies with meaningful Current Ratio only.
OMPI' s Current Ratio Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 3.91
Quick Ratio 4.34
OMPI's Quick Ratio is ranked lower than
99.99% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. OMPI: 4.34 )
Ranked among companies with meaningful Quick Ratio only.
OMPI' s Quick Ratio Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 4.34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.50
OMPI's Price/Net Cash is ranked lower than
99.99% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. OMPI: 0.50 )
Ranked among companies with meaningful Price/Net Cash only.
OMPI' s Price/Net Cash Range Over the Past 10 Years
Min: 10.4  Med: 19.05 Max: 385
Current: 0.5
10.4
385
Price/Net Current Asset Value 0.40
OMPI's Price/Net Current Asset Value is ranked lower than
99.99% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. OMPI: 0.40 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OMPI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 7.9  Med: 11.80 Max: 23.2
Current: 0.4
7.9
23.2
Price/Tangible Book 0.10
OMPI's Price/Tangible Book is ranked lower than
99.99% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. OMPI: 0.10 )
Ranked among companies with meaningful Price/Tangible Book only.
OMPI' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.3  Med: 4.60 Max: 26.4
Current: 0.1
3.3
26.4
Price/Graham Number 0.10
OMPI's Price/Graham Number is ranked lower than
99.99% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 2.88 vs. OMPI: 0.10 )
Ranked among companies with meaningful Price/Graham Number only.
OMPI' s Price/Graham Number Range Over the Past 10 Years
Min: 1.4  Med: 2.10 Max: 6
Current: 0.1
1.4
6
Earnings Yield (Greenblatt) (%) 7.20
OMPI's Earnings Yield (Greenblatt) (%) is ranked lower than
100% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. OMPI: 7.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OMPI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.1  Med: 9.20 Max: 24.6
Current: 7.2
4.1
24.6
Forward Rate of Return (Yacktman) (%) 7.22
OMPI's Forward Rate of Return (Yacktman) (%) is ranked lower than
99.99% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.20 vs. OMPI: 7.22 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
OMPI' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -8.8  Med: 3.20 Max: 34.3
Current: 7.22
-8.8
34.3

More Statistics

Short Percentage of Float0.00%
52-Week Range $10.70 - 25.60
Shares Outstanding (Mil)17.43

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)